












Abstract: Drug overdose is one of the major 
causes of death among young people in Europe. 
Naloxone is an effective antidote that can reverse 
opioid (including synthetic opioid) intoxication. As 
overdoses quite often occur in the presence of 
peers or family members, programmes that 
enable bystanders to provide first aid and 
administer naloxone before an ambulance arrives 
can save lives.
We conducted a systematic review of the 
available studies on take-home naloxone to 
reverse opioid overdose and included 21 studies 
for analysis (with various study designs). There is 
evidence from one interrupted time-series study, 
involving 2 912 opioid users at risk of overdose in 
19 communities followed up for seven years, that 
educational and training interventions 
complemented by take-home naloxone decrease 
overdose-related mortality.
There is weaker, but consistent, evidence that 
similar interventions for opioid-dependent 
patients and their peers effectively improve 
knowledge while forming positive attitudes to the 
correct use of naloxone and the management of 
witnessed overdoses. 
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benzodiazepines), as well as use of a combination of 
substances (polysubstance use) (Giraudon et al., 2013). In 
addition, in a substantial number of deaths, evidence of 
polydrug use (heroin in combination with other central 
nervous system depressants such as alcohol or 
benzodiazepines) was found. Among the new psychoactive 
substances (NPSs) are synthetic opioids, which have emerged 
as a key concern because of links to serious adverse events 
such as fatal and non-fatal intoxications (EMCDDA, 2014a), 
for example fentanyls causing fatal overdoses, particularly in 
east and central European countries (EMCDDA, 2012).
Overdose risk is influenced by individual, situational and 
organisational factors (Figure 1). Beyond the type of 
substance used and the route of administration, the 
circumstances of use also affect the probability of overdose.
Risk factors can include interrupted treatment provision 
because of discontinuous treatment and care, completion of 
the detoxification process or discharge from drug-free 
treatment (Cornish et al., 2010). In fact, although the majority 
of deaths occur in individuals with a history of opioid 
addiction, most of these individuals commonly have a reduced 
tolerance to opioids at the time of their death (Darke et al., 
2007). This implies an increased risk linked to relapse into use 
after a period of abstinence, for example following release 
from detention (Binswanger et al., 2013; Zlodre and Fazel, 
2012). Furthermore, occasional users of NPSs can also 
experience opioid overdose (EMCDDA, 2013b).
I Background
Drug use is one of the major causes of health problems and 
mortality among young people in Europe, and it can account 
for a considerable proportion of deaths among adults. The risk 
of premature death among injecting drug users can be 15 
times higher than in the general population of the same age 
group (Mathers et al., 2013). Some studies show that one third 
to one half of deaths among drug users may be caused by 
overdose (Bargagli et al., 2006; Degenhardt et al., 2011; 
EMCDDA, 2011, 2013a). Combined with acquired immune 
deficiency syndrome (AIDS), overdose represents the primary 
cause of death among people who inject drugs.
Drug overdose accounts for approximately 3.5 % of all deaths 
in adult males under 40 years of age (Eurostat, 2012, cited in 
EMCDDA, 2013a). In absolute numbers in 2012, for example, 
there were 6 100 overdose deaths across Europe.
In particular, the use of heroin and other opioids contributes 
disproportionately to drug-related deaths: overdose 
represents a common event among opioid users (EMCDDA, 
2011, 2013a). Injecting drug use in Europe is becoming less 
prevalent (EMCDDA, 2013b) but mortality among injectors 
remains high (Mathers et al., 2013), and injecting drug use is 
associated with increased risk for fatal and non-fatal 
overdoses compared with non-injected routes of 
administration (Darke et al., 2007). Among the substances 
associated with the risk of overdose are opioids (including 
prescription and non-medical use) and non-opioids (e.g. 
FIGURE 1
Risk factors for overdose
Adapted from WHO (2014). HIV, human immunodeficiency virus
Access n Family members of people in possession of strong opioids
n  Injected use
n  Use of high-dosage prescription opioids
n  Use in combination with other sedating substances
n  Reduced tolerance (following detoxification, release from incarceration, 
cessation of treatment)
n  Opioid users with other significant medical conditions (HIV positive, liver 
or lung disease, depression)
Dependence
Use
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I Overdose prevention interventions
Several interventions are implemented with the direct aim of 
preventing opioid overdose, whereas other interventions have 
an indirect effect on reducing overdoses and overdose 
mortality.
These interventions act at different stages and levels of risk 
and they can address (i) the general population, such as 
drug-use prevention interventions; (ii) drug users, for example 
induction into treatment; (iii) active drug users, as is the case 
with harm reduction strategies; and (iv) those experiencing an 
ongoing overdose, in order to reduce lethality (Figure 2).
I  Cause of death in opioid overdose and the role of naloxone
Opioid overdose is characterised by drowsiness or coma, 
decreased respiratory rate, abnormally slow breathing, 
pinpoint pupils and possibly apnoea (Boyer Edward, 2012). 
Death from opioid overdose is caused primarily by respiratory 
depression leading to cardiac arrest. Naloxone is an opioid 
antagonist that can reverse the effects of opioids, including 
respiratory depression, in the body within a few minutes. In 
the absence of an agonist drug (such as an opioid) naloxone is 
almost inert, but in individuals who are in acute respiratory 
depression caused by an opioid overdose naloxone can 
normalise respiration, level of consciousness, pupil size, bowel 
activity and other signs and symptoms of overdose (Katzung, 
1995). As naloxone, like naltrexone, has antagonistic effects, it 
can precipitate opioid withdrawal syndrome in those under 
the influence of opioid agonists.
It is standard practice for ambulance personnel to administer 
naloxone to victims of acute opioid overdose, as well as 
perform resuscitation techniques. When emergency 
personnel intervene in sufficient time, opioid overdoses can be 
effectively reversed. Nevertheless, it has been observed that 
although bystanders are present during the majority of 
overdoses they fail to call for ambulance services. The person 
most likely to be present during an overdose is another drug 
user, and a large proportion of heroin users have witnessed an 
overdose (Darke et al., 2007; Frischer and Baldacchino, 2012). 
Therefore, they are reluctant to call for medical help for fear of 
possible legal consequences for themselves (Frischer and 
Baldacchino, 2012).
On the other hand, it has been reported that laypeople present 
during overdoses attempt a variety of methods to rescue the 
FIGURE 2
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I Methods
We included randomised controlled trials (RCTs), controlled 
clinical trials (CCTs), controlled cohort studies, interrupted 
time-series analyses, cross-sectional surveys, case series and 
population-based results of programme implementations. We 
considered studies enrolling current or former opioid injectors, 
their parents and their peers. All participants were included 
regardless of age, gender and nationality. The experimental 
intervention was take-home emergency naloxone 
accompanied or not by explanatory leaflets, education and 
training for opioid users, peers and families; the control 
intervention was intervention as usual (e.g. information on the 
risks of overdose) or no intervention.
The types of outcomes were as follows: (a) knowledge, 
management and first aid in overdose cases; (b) attitudes 
towards naloxone (acceptability and willingness to use); (c) 
management of witnessed overdoses — use of naloxone and 
adequacy of care given to the patient; (d) adverse events 
following administration of naloxone to reverse overdose; and 
(e) deaths due to overdose.
I Search strategy
The following electronic databases were searched (Figure 3): 
Cochrane Drugs and Alcohol Group (CDAG) Specialized 
Register; the Cochrane Central Register of Controlled Trials 
(CENTRAL) Issue 6, 2013; PubMed (also known as MEDLINE, 
1996 to June 2013); EMBASE (Elsevier, EMBASE.com, 1974 
to June 2013); the Cumulative Index to Nursing and Allied 
Health Literature (CINAHL, EBSCOhost, 1982 to June 2013); 
and the Web of Science (1991 to June 2013). The detailed 
search strategy for each database is reported in Annex 4.
The following were also searched: (a) the reference lists of all 
relevant papers to identify further studies; (b) some of the 
main electronic sources of ongoing trials, including 
metaRegister of Controlled Trials (mRCT) (www.controlled-
trials.com), ClinicalTrials.gov (www.clinicaltrials.gov) and the 
WHO International Clinical Trials Registry Platform (ICTRP) 
(www.who.int/ictrp/search/en); (c) conference proceedings 
likely to contain trials relevant to the review (College on 
Problems of Drug Dependence — CPDD); and (d) national 
focal points for drug research (e.g. National Institute of Drug 
Abuse and National Drug and Alcohol Research Centre).
The search was not limited by language of publication.
Data collection and analysis
Two authors independently inspected the search hits by 
reading titles and abstracts. The full text of each potentially 
victim, including a number of ineffective techniques. These 
include injection of other drugs (such as cocaine) or salt and 
allowing the victim to ingest ice or bathe in cold water (Strang 
et al., 2013). These and other potentially harmful practices 
show the willingness of bystanders to help.
The distribution of naloxone to potential victims of heroin 
overdose and to those who may happen to assist during an 
opioid overdose — together with a brief educational 
intervention that aims to instruct how to recognise an 
overdose, assist the patient and administer naloxone — has 
been proposed as an innovative approach to reduce overdose 
fatalities (Clark, 2014). Specifically, programmes for the 
distribution of naloxone aim to increase the availability of 
naloxone in the community and, consequently, decrease 
overdose fatalities.
Naloxone injection is a liquid formulation that can be 
injected intravenously, intramuscularly or 
subcutaneously. Prefilled auto-injection devices 
containing a solution for injection into a muscle or under 
the skin also exist, as well as devices to administer 
naloxone intranasally (sprayed into the nose) 
(MedlinePlus, accessed May 2014). Nevertheless, 
intranasal administration is an off-label use 
(WHO, 2014).
What naloxone formulations are available?
I Why is this review important?
Implementation of take-home naloxone has been 
recommended in the UK by the Advisory Council on the 
Misuse of Drugs (ACMD, 2012) since 2000, recognising the 
potential contribution of this intervention to the reduction in 
the number of overdose mortalities and the need for naloxone 
to be more widely available. Naloxone administration is 
available in seven European countries, namely Denmark, 
Germany, Estonia, Spain, Italy, United Kingdom and Norway 
(see Annex 1 and EMCDDA, 2014b). It is therefore important 
to exchange existing knowledge on such an intervention to 
enable potential implementers to take informed decisions.
I Objective
The objective of this overview is to assess the effect of 
take-home emergency naloxone and educational intervention 
on knowledge improvement, naloxone use, management of 
overdoses witnessed and death as a result of overdose.
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performed using the approach recommended by the Cochrane 
handbook; the first step is to describe what is reported in the 
study and the second is to judge the risk of bias in terms of low, 
high or unclear risk (Higgins and Green, 2011).
For a detailed description of the criteria used in this overview 
to assess each type of study design, see Annex 5.
relevant study located in the search was obtained and 
independently assessed for inclusion. Doubts were resolved 
through discussion between the authors. Data were extracted 
from included studies using a structured data extraction form. 
One author extracted data and a second investigator checked 
it. Differences were resolved through discussion and 
consensus. A risk-of-bias assessment for RCTs and CCTs was 
FIGURE 3
Flow chart of study assessment and selection
1 542 records identified through database searching 
(PubMED: 471; EMBASE: 641, CENTRAL: 46; CINAHL: 61; 
WEB OF SCIENCE: 302; CDAG Register: 21)
2 additional records identified 
through other sources
1 045 records after duplicates removed
1 045 records screened 975 records excluded based  
on title and abstract
46 full-text articles  
excluded, with reasons
70 full-text articles  
assessed for eligibility
21 studies included in  
qualitative synthesis  
– 2 ongoing studies
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Study design and location
One study was a RCT, three were case-series and 17 were 
pre-post studies.
Furthermore, two ongoing trials were identified and the 
descriptions of the protocols are reported in the Conclusions 
(pp. 11–12).
Of the included studies, 14 were carried out in the USA, five in 
the UK, one in Canada and one in the UK and Germany.
Participants
In all the included studies participants were opioid users and 
their parents or carers. In one study (Walley et al., 2013a) 
participants were patients enrolled on methadone 
maintenance programmes. The sample size varied greatly, 
ranging from 19 to 53 032 subjects enrolled and assessed.
Excluded articles
Forty-six full text articles were excluded (see ‘Excluded 
studies (articles)’ in References). The reasons for exclusion 
were as follows: study design not in the inclusion criteria 
(narrative review, editorial, letter, case report) (n = 18); types 
of intervention not in the inclusion criteria (take-home 
naloxone not provided) (n = 17); outcome of interest not 




Twenty-two publications, covering 21 studies, were included 
in the present overview (two publications referred to the same 
study whereas one publication reported the results of two 
programmes). For more details see Annex 1.
The main objective of epidemiological research is to find 
explanations for the manifestation of diseases in the 
population. Bias is a false result influenced by uncontrolled 
factors. A typical example of bias is an unwanted selection 
of the population studied so that the sample does not 
adequately represent the target population. Bias has been 
defined as ‘incorrect assessment of the association 
between an exposure and an effect in the target population’ 
(Delgado-Rodríguez, 2004, p. 635). The quality of studies is 
highly linked to the reduction of possible bias. There are 
many known types of bias, including selection bias, the risk 
of selecting the sample for uncontrolled characteristics 
(Delgado-Rodríguez, 2004); indication bias, which emerges 
from RCTs when patients, instead of being assigned to 
treatment randomly, are assigned on the basis of some 
characteristic, for example a higher susceptibility to a 
disease; detection bias, when some patients have a higher 
chance of being diagnosed because they are tested more 
often owing to a concurrent condition (e.g. those with 
diabetes who are tested daily have more chance of testing 
positive for hyperglycaemia than those who are not tested);  
assessment bias, when the professionals assessing the 
results of an intervention are influenced by their knowledge 
of the interventions provided (a typical example is a nurse 
who measures body temperature more often or more 
accurately in patients given placebo than in those given the 
active substance); and performance bias, when patients are 
given different interventions not on the basis of random 
allocation but because of some other characteristic or 
situation. In addition, publication bias is a distortion in the 
availability of studies. It has been observed that studies 
with positive results have more probability of being 
published and, in general, are published faster and in higher 
impact journals (Dubben and Beck-Bornholdt, 2005).
Why are some studies defined as ‘blinded’?
Blinding refers to all the strategies that are put in place to 
prevent knowledge of the intervention influencing behaviour 
(of patients, clinicians, carers or outcome assessors), which 
could lead to biased results. In a RCT, patients are usually 
blinded to the intervention so that they cannot over- or 
under-report some symptoms. The same strategy applies to 
the assessors. The term ‘double blinded’ describes a 
situation in which neither the patient nor the assessor of 
the outcome (e.g. the professional asking questions) is 
aware of the treatment provided to the specific patient.
What is ‘bias’?
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Interventions
In all the included studies (Table 1) the intervention consisted of 
(i) education and information on the identification of overdose 
risk factors, the usual signs of opiate overdose, appropriate 
methods for dealing with an overdose, the use of naloxone, 
methods for administering naloxone, period of time over which 
naloxone is effective and recommended injection sites; (ii) 
practical training; and (iii) provision of one or two doses of 
naloxone as prefilled syringes. In three studies the device for 
administering intranasal naloxone was provided to participants.
I Outcome measures
The outcome measures were as follows:
Knowledge of risk factors of overdose, signs of opiate 
overdose, correct use of naloxone, management of witnessed 
overdose: training provision is aimed at enabling laypeople to 
proactively manage an overdose occurrence. For this reason, 
some of the studies primarily measure how effective the 
training interventions were in communicating the basic 
information required in such an occurrence. These outcomes 
were covered by eight studies (Bennett and Holloway, 2012; 
Gaston et al., 2009; McAuley et al., 2010; Seal et al., 2005; 
Strang et al., 2008; Tobin et al., 2009; Wagner et al., 2010; 
Williams et al., 2014).
Attitudes: willingness to use naloxone, confidence in and 
acceptability of naloxone. Acquisition of knowledge may not 
be associated with preparedness to put it into practice, 
especially under emotional circumstances. These outcomes 
were covered by seven studies (Bennett and Holloway, 2012; 
Galea et al., 2006; McAuley et al., 2010; Strang et al., 2008; 




Naloxone hydrochloride (2 mg/2 ml prefilled 
syringe) for taking away and 1-hour training 
session
The control group was asked only to read a 
short booklet on overdose risk factors, opioid 
overdose signs, actions to take in an overdose 
and basic information about naloxone
Williams et al. (2014)
Educational and training programme with 
the provision of take-home naloxone
No comparison Gaston et al. (2009), Seal et al. (2005), Strang et al. 
(2008)
Implementation of education and naloxone 
distribution programmes realised at city or 
regional level
N/A (but one study compared different levels 
of intensity of intervention)
Bennett and Holloway (2012), Bennett et al. (2011), 
Dettmer et al. (2001), Enteen et al. (2010), Galea et al. 
(2006), Gaston et al. (2009), Heller and Stancliff (2007), 
Leece et al. (2013), McAuley et al. (2010), Maxwell et al. 
(2006), Piper et al. (2008), Tobin et al. (2009), Wagner 
et al. (2010), Walley et al. (2013a), Walley et al. (2013b), 
Wheeler et al. (2012), Yokell et al. (2011)
Implementation of education and intranasal 
naloxone distribution programmes realised 
at city or regional level
N/A Doe-Simkins et al. (2009)
N/A, not applicable.
Several study designs are available in the epidemiologist’s 
toolbox to assess the effectiveness of interventions. The 
choice of study design is influenced by many factors, 
including the type of research question, the resources 
available, the setting and how common a health condition 
is. The studies included in the present review are: 
randomised controlled studies — typically used to assess 
the effectiveness of interventions, this study design 
randomly allocates patients to one intervention or a control;
clinical controlled studies — studies in which patients 
are assigned to one intervention or a control, but not 
randomly;
case-series studies — studies in which a consecutive 
series of patient cases described;
time-series studies — studies in which the end points 
(e.g. the mortality in a town) are measured at different 
points in time;
pre–post studies — studies in which the end points are 
measured before and after the study interventions.
Study design
Overdose management: including calling for an ambulance, 
putting the patient in the recovery position and performing 
cardiopulmonary resuscitation. Twelve studies assessed 
whether or not the target population followed the instructions 
given during the training sessions (Bennett et al., 2011; 
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The interrupted time-series (ITS) analysis (Walley et al., 
2013b) was judged to be at low risk of bias for all the items 
assessed (clearly defined point in time when the intervention 
occurred; at least three data points before, and three after, the 
intervention; protection against secular changes; protection 
against detection bias; blinded assessment of primary 
outcomes) and at unclear risk of bias for the completeness of 
data sets (Annex 2).
Even if a validated checklist was not available to assess the 
risk of bias of the other study designs, we noted that the 
generalisability of the results is limited. All but one study 
(Bennett and Holloway, 2012) had no control groups. Bennett 
and Holloway (2012) had a control group of 50 participants 
compared with 521 individuals exposed to the intervention. 
Four studies (Galea et al., 2006; Gaston et al., 2009; McAuley 
et al., 2010; Seal et al., 2005) included a very small number of 
patients (n = 25, n = 70, n = 19 and n = 24, respectively) and 
the method for the sample selection was not reported. In five 
studies there were many patients lost at follow-up: 20 % in 
Galea et al. (2006), 35 % in Gaston et al. (2009), 23 % in 
Strang et al. (2008), 66 % in Tobin et al. (2009) and 29 % in 
Wagner et al. (2010). In Piper et al. (2008) detailed information 
on the management of overdose was reported for 61 % of the 
overdoses for which naloxone was administered. In five 
studies (Bennett et al., 2011; Bennett and Holloway, 2012; 
Dettmer et al., 2001; Enteen et al., 2010; Yokell et al., 2011) the 
results about naloxone use and management of overdose 
were reported only for those participants who voluntarily 
reported back and/or returned for a refill of naloxone, who 
constituted a small percentage of the overall sample: 33 % in 
Bennett et al. (2011), 5.3 % in Bennett and Holloway (2012), 
41 % in Dettmer et al. (2001), 24 % in Enteen et al. (2010) and 
8.3 % in Yokell et al. (2011). In Leece et al. (2013), Maxwell et 
al. (2006) and Wheeler et al. (2012) there was no information 
about the method used for collecting data on the 
management of overdose. All the outcomes were self-
reported.
I Effect of the interventions
Overall, the available studies considered in the present 
overview showed that naloxone provision among drug users 
and their peers may be an effective strategy to reduce fatal 
overdoses (Table 2). The outcomes measured included the 
improvement of knowledge on how to manage an overdose 
and the willingness to put into practice the acquired 
knowledge, along with the process and the outcomes of 
overdose management. The studies also measured the 
percentage of naloxone administration in the event of 
overdose and the requests to refill naloxone, and the fatal 
cases in spite of naloxone administration.
Bennett and Holloway, 2012; Dettmer et al., 2001; Doe-
Simkins et al., 2009; Enteen et al., 2010; Galea et al., 2006; 
Gaston et al., 2009; McAuley et al., 2010; Piper et al., 2008; 
Seal et al., 2005; Tobin et al., 2009; Wagner et al., 2010).
Naloxone administration: all but three studies (Heller and 
Stancliff, 2007; Maxwell et al., 2006; Wheeler et al., 2012) 
reported the number of times when naloxone was given to 
patients, but only 13 studies reported the number of 
overdoses witnessed, allowing calculation of the percentage 
of overdoses in which naloxone was given. Two studies (Leece 
et al., 2013; Tobin et al., 2009) did not report the number of 
overdoses witnessed, but only the number of participants who 
used naloxone, without specifying if they did so on one or 
more occasions.
Request for naloxone refill, naloxone lost or stolen: a proxy 
outcome for actual use and/or interest in using the naloxone 
at occurrence. These outcomes were covered by nine studies 
(Bennett et al., 2011; Doe-Simkins et al., 2009; Enteen et al., 
2010; Galea et al., 2006; Gaston et al., 2009; Piper et al., 2008; 
Tobin et al., 2009; Wagner et al., 2010; Walley et al., 2013a and b).
Death due to overdose: 11 studies (Bennett et al., 2011; 
Bennett and Holloway, 2012; Dettmer et al. 2001; Doe-
Simkins et al., 2009; Enteen et al., 2010; Galea et al., 2006; 
McAuley et al., 2010; Piper et al., 2008; Seal et al., 2005; 
Strang et al., 2008; Wagner et al., 2010) assessed this 
outcome among subjects with overdoses witnessed by study 
participants; one study (Walley et al., 2013b) reported 
overdose deaths in communities covered by the intervention 
compared with communities not covered by the intervention. 
Three studies (Heller and Stancliff, 2007; Maxwell et al., 2006; 
Wheeler et al., 2012) reported only the total number of 
overdoses reversed.
I Methodological quality
The assessment of methodological quality using standardised 
criteria was possible for only two studies: the RCT (Williams et 
al., 2014) and the interrupted time-series study (Walley et al., 
2013b). Three studies were uncontrolled case series and all 
the other studies used a pre–post (or only post) evaluation 
design without a control group for which standardised and 
validated checklists for quality assessment were not available.
The RCT was judged to be at low risk of selection bias but at 
high risk of performance and detection bias. This is because it 
was an open-label study with subjective outcome measures 
based on self-reported data. It was also judged to be at risk of 
attrition bias because the analysis was done on a per-protocol 
basis with a high rate of patients lost at follow-up and 
unbalanced between the arms of the study (Annex 2).
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studies on this topic have been missed is small, but the 
possibility of some unpublished studies not being retrieved 
cannot be ruled out.
I Conclusions
There is evidence that educational and training interventions 
with provision of take-home naloxone decrease overdose-
related mortality.
There is weaker, but consistent, evidence that educational and 
training interventions with naloxone provision for opioid-
dependent patients and their peers is effective in improving 
knowledge about and creating positive attitudes to the correct 
use of naloxone and management of witnessed overdoses. 
There is sparse evidence that people return for naloxone refill.
Take-home naloxone provision is an emergency life-saving 
intervention. As with other types of public health programmes 
relying on layperson interventions in critical situations, it is 
difficult to assess their effectiveness with properly designed 
experimental studies. By analogy with the provision of public 
access defibrillators (PADs) for out-of-hospital cardiac arrest, 
for example, the factors contributing to survival rates are many 
and difficult to control in an experimental study design. 
Nevertheless, although the evidence in support of PADs is 
scarce, the available systematic reviews of the literature 
suggest the implementation of such an intervention (Clare, 
2006; Smith et al., 2007) for the actual or potential reduction 
of fatal cases.
Prospective controlled cohort studies of good methodological 
quality comparing communities where the intervention is 
implemented with communities where it is not implemented 
or implemented at a lower intensity may contribute to the 
supporting evidence. Those studies should be based on 
current multiple-source data collections (including emergency 
and hospital data, along with mortality data) and may assess 
the impact of the intervention on public health and 
participants’ behaviour (incidence of overdose, management 
of witnessed overdose, outcome of overdoses, naloxone 
provision and naloxone refill).
New initiatives have emerged quickly over recent years in 
various regions of the world. This is driven in part by the 
epidemic of opioid-related deaths (heroin and non-heroin) in 
the USA. In Europe, naloxone programmes are now broadly 
available. Since September 2013, Estonia has had a naloxone 
programme to tackle the alarming increase in deaths caused 
by illicit use of fentanyl. Most recently, Norway began a pilot of 
a nasal spray naloxone programme.
I Discussion
I Summary of the main results
Improving knowledge on opioid overdose and enabling 
preparedness to intervene
This outcome included knowledge about signs of overdose, 
the correct management of patients and naloxone use; and 
attitudes (willingness to use naloxone, confidence in and 
acceptability of naloxone). The educational and training 
intervention with naloxone provision seems to be effective in 
improving knowledge about signs of overdose, the correct 
management of patients and naloxone use in all the retrieved 
studies, including the randomised trial and the uncontrolled 
pre–post studies. The one randomised trial also suggests that 
attitudes towards the use of naloxone have improved. The 
management of witnessed overdoses seems to be positively 
influenced by the educational and training intervention in 
patients who returned for naloxone refill or who were not lost 
at follow-up.
Management of witnessed overdose 
(naloxone administration)
Naloxone was administered in a median of 67 % of overdoses 
witnessed by participants who returned for naloxone refill or 
who were not lost at follow-up (Table 2). The data come only 
from uncontrolled studies.
Death due to overdose and survival rate
The risk of opioid-related overdose fatalities was significantly 
lower in communities providing naloxone distribution and 
overdose management education than in communities 
without programme implementation. This was shown in an ITS 
analysis of more than 2 900 subjects from 19 communities 
with a follow-up of 7 years (Walley et al., 2013b). Furthermore, 
all the other studies found a high survival rate.
I Potential bias in the review process
It was not possible to assess the risk of publication bias using 
a funnel plot because a meta-analysis was not performed. 
Unpublished studies were searched on websites of 
conference proceedings, ongoing trials were searched, 
comprehensive bibliographic searches of many databases, 
unrestricted by date or language, were undertaken and 
reference lists of retrieved studies and narrative reviews were 
inspected. For these reasons the probability that relevant 
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been trained and issued with take-home naloxone kits for 
distribution will fall into the intervention group. Patients 
attended to by paramedics following usual practice (until they 
receive their training and take-home naloxone kits) will fall into 
the control group. Many outcomes will be assessed, with the 
aim of defining the primary outcome of the definitive trial.
This overview reached similar conclusions to those of a 
recently published review (Clark et al., 2014) that included 19 
of the 21 studies in our work, including the RCT by Williams et 
al. (2014), which probably contributed to our more confident 
conclusions.
With regard to guidelines to support the implementation of 
naloxone availability outside the healthcare system, the World 
Health Organization published a document for global use. 
Some European countries have national guidelines; these can 
be found in the EMCDDA’s Best practice portal.
In this context, the rapid identification and dissemination of 
the available evidence can be helpful to refine these 
programmes, if needed, or to scale up their implementation 
and coverage.
Furthermore, some studies are ongoing and their results will 
greatly contribute to the body of evidence. These include the 
N-ALIVE trial (Strang et al., 2013), which plans to involve 5 600 
prisoners on release in the initial pilot randomised phase then 
extend to its randomised sample size of 56 000 for the full 
trial. Participants will receive emergency naloxone with 
instructions for it to be given by the much simpler 
intramuscular route. The PATHFINDER feasibility study South 
Wales (Moore, ongoing) aims to assess whether it is possible 
for paramedics to supply take-home naloxone kits to patients 
whom they have treated and who have subsequently 
recovered from an opioid overdose. Paramedics will be 
randomly allocated to training over the first 4 months of the 
12-month trial. Patients attended to by paramedics who have 
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I Annex 6
I  Criteria for risk of bias assessment: case–control 
studies
Selection
1)  Adequate definition of the cases
a)  yes, with independent validation
b)  yes, e.g. record linkage or based on self-reports
c)  no description
2)  Representativeness of the cases
a)  consecutive or obviously representative series of cases
b)  potential for selection biases or not stated
3)  Selection of controls
a)  community controls
b)  hospital controls
c)  no description
4)  Definition of controls
a)  no history of disease (end point)
b)  no description of source
Comparability
5)  Comparability of cases and controls on the basis of the 
design or analysis
a)  study controls for the most important factor
b)  study controls for any additional factor
c)  no control or adjustment for potential confounders
Exposure
6)  Ascertainment of exposure
a)  secure record (e.g. surgical records)
b)  structured interview where blind to case/control status
c)  interview not blinded to case/control status
d)  written self-report or medical record only
e)  no description
7)  Same method of ascertainment for cases and controls
a)  yes
b)  no
8)  Non-response rate
a)  same rate for both groups
b)  non-respondents described
c)  rate different and no designation
Criteria for risk of bias assessment: cohort studies
Selection
1)  Representativeness of the exposed cohort:
a)  truly representative of the average in the community
b)  somewhat representative of the average in the 
community
c)  selected group of patients
d)  no description of the derivation of the cohort
2)  Selection of the non-exposed cohort
a)  drawn from the same community as the exposed cohort
b)  drawn from a different source
c)  no description of the derivation of the non-exposed 
cohort
3)  Ascertainment of exposure
a)  secure record
b)  structured interview
c)  written self-report
d)  no description





1)  Comparability of cohorts on the basis of the design or 
analysis
a)  study controls for the most important factor
b)  study controls for any additional factor
Outcome
1)  Assessment of outcome
a)  independent blind assessment
b)  record linkage
c)  self-report
d)  no description
2)  Was follow-up long enough for outcomes to occur?
a)  yes
b)  no
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b) NOT CLEAR because it is not reported in the paper
c)  Intervention was not independent of other changes over 
time
Protection against detection bias (intervention is unlikely to 
affect data collection)
a)  Intervention is unlikely to affect data collection (e.g. 
sources and methods of data collection were the same 
before and after the intervention)
b)  NOT CLEAR because it is not reported in the paper
c)  Intervention is likely to affect data collection (e.g. any 
change in source or method of data collection before vs. 
after the intervention)
Blinded assessment of primary outcome(s)
a)  Explicit statement of authors that the primary outcome 
variables were assessed blindly OR the outcome 
variables are objective, e.g. length of hospital stay, drug 
levels as assessed by a standardised test
b)  NOT CLEAR if not specified
c)  Outcomes were not assessed blindly
Completeness of data set
a)  Data set covers 80–100 % of total number of 
participants or episodes of care in the study
b)  NOT CLEAR if not specified
c)  Data set covers less than 80 % of the total number of 
participants or episodes of care in the study
3)  Adequacy of follow-up of cohorts
a)  complete follow-up — all subjects accounted for
b)  subjects lost to follow-up unlikely to introduce bias 
— small number lost (< 10 % or a description provided 
of those lost)
c)  no statement
Criteria for risk of bias assessment: interrupted time 
series
Clearly defined point in time when the intervention occurred.
a)  Intervention occurred at a clearly defined point in time
b)  NOT CLEAR because it is not reported in the paper
c)  Intervention did not occur at a clearly defined point in 
time
At least three data points before, and three after, the 
intervention.
a)  Three or more data points before and three or more data 
points recorded after the intervention
b)  NOT CLEAR because it is not reported in the paper
c)  Fewer than three data points recorded before, and three 
data points after, the intervention
Protection against secular changes (the intervention is 
independent of other changes).
a)  Intervention occurred independently of other changes 
over time
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